共 50 条
- [31] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative ColitisJOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 590 - 604Xu, YanAdedokun, Omoniyi J.Chan, DaphneHu, ChuanpuXu, ZhenhuaStrauss, Richard S.Hyams, Jeffrey S.Turner, DanZhou, Honghui
- [32] Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18): : 1723 - 1736Sandborn, William J.Su, ChinyuSands, Bruce E.D'Haens, Geert R.Vermeire, SeverineSchreiber, StefanDanese, SilvioFeagan, Brian G.Reinisch, WalterNiezychowski, WojciechFriedman, GaryLawendy, NervinYu, DahongWoodworth, DeborahMukherjee, ArnabZhang, HaiyingHealey, PaulPanes, Julian
- [33] Tofacitinib Plasma Concentration Monitoring Is Not Needed for Optimization of Induction Therapy in Moderate to Severe Ulcerative Colitis: Results of Pooled Exposure-Response Analyses of Phase 3 Induction StudiesGASTROENTEROLOGY, 2016, 150 (04) : S774 - S774Mukherjee, ArnabTsuchiwata, ShinichiDeng, ChenhuiVong, CamilleXie, RujiaMartin, Steven W.Yu, DahongWoodworth, Deborah A.Niezychowski, WojciechSu, Chinyu
- [34] Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative ColitisCLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (09) : 1814 - +Vande Casteele, NielsJeyarajah, JennyJairath, VipulFeagan, Brian G.Sandborn, William J.
- [35] Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitisCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1234 - 1243Kassir, NastyaZhu, RuiMoein, AnitaLangenhorst, JurgenRibbing, JakobZhang, RongTang, Meina T.Oh, Young S.Zhang, Wenhui
- [36] Exposure-response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1JOURNAL OF CROHNS & COLITIS, 2019, 13 : S377 - S378Rosario, M.Polhamus, D.Dirks, N.Lock, R.Yao, X.Chen, J.Chen, C.Sun, W.Feagan, B.Sandborn, W.D'Haens, G.
- [37] ANALYSIS OF HEMATOLOGICAL CHANGES IN TOFACITINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS ACROSS PHASE 3 INDUCTION AND MAINTENANCE STUDIESGASTROENTEROLOGY, 2019, 156 (06) : S1111 - S1111Lichtenstein, Gary R.Moore, Gregory T.Soonasra, ArifNduaka, Chudy I.Kwok, KennethWang, LisyLawendy, NervinChan, GarySu, ChinyuLoftus, Edward V.
- [38] Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studiesJOURNAL OF CROHNS & COLITIS, 2019, 13 : S351 - S352Lichtenstein, G. R.Moore, G. T.Soonasra, A.Nduaka, C. I.Kwok, K.Wang, L.Lawendy, N.Chan, G.Su, C.Loftus, E. V., Jr.
- [39] Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate-to-severe ulcerative colitis: results from a multicentre open-label studyJOURNAL OF CROHNS & COLITIS, 2016, 10 : S62 - S63Adedokun, O. J.Chan, D.Padgett, L.Xu, Y.Hyams, J.Turner, D.Xu, Z.Davis, H.Strauss, R.
- [40] Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studiesJOURNAL OF CROHNS & COLITIS, 2016, 10 : S73 - S74Mukherjee, A.Tsuchiwata, S.Deng, C.Vong, C.Xie, R.Martin, S. W.Yu, D.Woodworth, D.Niezychowski, W.Su, C.